EMEA-001143-PIP01-11-M02

Key facts

Invented name
Cometriq
Active substance
cabozantinib
Therapeutic area
Oncology
Decision number
P/0331/2019
PIP number
EMEA-001143-PIP01-11-M02
Pharmaceutical form(s)
  • Age-appropriate oral solid dosage form
  • Tablet
  • Capsule (hard)
Condition(s) / indication(s)
Treatment of solid malignant tumours
Route(s) of administration
Oral use
Contact for public enquiries
Ipsen Pharma

Tel.: +33 158335427
E-mail: abdelali.majdi@ipsen.com

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating